FDA Approves Revolutionary Pancreatic Cancer Therapy

The U.S. Food and Drug Administration (FDA) has given the green light to daraksonrasib, a groundbreaking therapy for pancreatic cancer. Marketed as Rasonque by Revolution Medicines, this drug has shown remarkable results in clinical trials, nearly doubling the overall survival time for patients battling one of the world's deadliest cancers.

A late-stage clinical trial involving 500 patients revealed that those who took the tablet-form drug daily lived an average of 13.2 months. This significantly contrasts with the 6.6 months survival rate for patients receiving traditional chemotherapy. The FDA described the drug as an "important new option for patients facing an extremely difficult cancer that has historically been very challenging to treat."

Daraksonrasib works by targeting and blocking the KRAS gene mutation, which is present in over 90% of pancreatic tumors and drives cancer cell growth. Pancreatic cancer affects approximately 67,000 people annually in the U.S. and is known for its high mortality rate, with over half of patients dying within three months of diagnosis.

“

important new option for patients facing an extremely difficult cancer that has historically been very challenging to treat.

The FDA had previously granted daraksonrasib "Breakthrough Therapy" status in 2025, a designation for therapies treating serious conditions that warrant expedited review. The agency's accelerated approval, six months ahead of schedule, was attributed to its "unprecedented results in an area with a high unmet need for new therapies," according to Angelo de Claro, director of the FDA's Center for Oncologic Excellence.

While the therapy offers significant hope, common side effects include rash, diarrhea, nausea, fatigue, and vomiting. Approximately 44% of patients on daraksonrasib experienced serious side effects, compared to 57.5% in the chemotherapy group. Former U.S. Senator Ben Sasse, who is participating in a clinical trial for the drug after his Stage IV pancreatic cancer diagnosis, reported that the therapy has helped shrink his tumors.

“

unprecedented results in an area with a high unmet need for new therapies.